Quest Diagnostics is Thursday's IBD Stock Of The Day. Shares are lingering in a buy zone, helped by a Texas court's ruling.
Fintel reports that on April 2, 2025, Redburn Atlantic initiated coverage of Quest Diagnostics (NYSE:DGX) with a Buy ...
Redburn Atlantic analyst Jamie Clark initiated coverage of Quest Diagnostics (DGX) with a Buy rating and $195 price target Don't Miss Our End ...
The most recent lawsuit is from winter 2024, when the California attorney general announced a $5 million settlement with ...